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Sir: We read the article “transplacental passage of a
nonionic contrast agent” by Vanhaesebrouck et al. [5] with
interest. The authors present a case report and make
statements in the discussion regarding the neural tolerance
of the contrast agent used (iopromide, Ultravist). They state
that iopromide is not indicated for intrathecal use and cite
an article by Caillé and Allard [2] as the reference for such
alleged severe reactions associated with the intrathecal use
of iopromide.
We would like to comment on this:
There is considerable safety experience with this con-
trast agent. Since its launch in 1985 more than 90 million
patients have been exposed to it, mostly with intravascular
applications. However, iopromide (Ultravist 240) has also
been investigated for the indication of myelography [1, 4]
and has regulatory approval and is used in this indication in
several countries. The article by Caillé and Allard [2] is not
correctly cited in this context, as the nonionic monomers
discussed do not include iopromide nor are any severe
neurologic adverse reactions identified as related to its use.
Regarding neural tolerance it is also worthy to mention that
iopromide has been investigated, has regulatory approval
and is widely used in cerebral angiography [3]. Also in this
indication its neural tolerance has been shown to not differ
from similar nonionic agents.
Yours sincerely,
Alexander Michel, M.D. M.Sc.
Global Medical Safety Surveillance,
Schering AG, 13342 Berlin, Germany
E-mail address: Alexander.Michel@Schering.de
Ginette B. Jacob, M.D.
Medical Affairs, Diagnostic Imaging
Berlex Inc, Wayne, NJ 07470-6806, USA
References
1. Albrecht A, Golebiowski M, Kornienko VN, Nikitin V, Palmers
Y, Trzebicki J, Twarkowski P, Wegener R (1999) A double-
blind, prospective, randomized, multicenter group comparison
study of iopromide 240 vs iohexol 240 in myelography. Eur
Radiol 9:1901–1908
2. Caillé JM, Allard M (1988) Neurotoxicity of hydrosoluble
iodine contrast media. Invest Radiol 23:S210–S212
3. Haughton VM, Papke A, Hyland D, Drayer BP, Osborn AG,
Maravilla K, Hilal SK (1994) Safety and efficacy of iopromide
in cerebral arteriography. Invest Radiol 29:S94–S97
4. Kugoev AI, Krause W, Timerbaeva SL, Wegener R (1999)
Pharmacokinetics and tolerability of iopromide 240 after lum-
bar myelography. Invest Radiol 34:692–697
5. Vanhaesebrouck P, Verstraete AG, De Praeter C, Smets K,
Zecic A, Craen M (2005) Transplacental passage of a nonionic
contrast agent. Eur J Pediatr 164:408–410
Letter to the editor
A. Michel (*)
Global Medical Safety Surveillance,
Schering AG,
13342 Berlin, Germany
e-mail: Alexander.Michel@Schering.de
G. B. Jacob
Medical Affairs,
Diagnostic Imaging Berlex Inc,
Wayne, NJ 07470-6806, USA
Eur J Pediatr
DOI 10.1007/s00431-005-0072-1
CORRESPONDENCE
Piet Vanhaesebrouck
Comment to “Transplacental passage of a nonionic
contrast agent”
Reply
# Springer-Verlag 2005
Sir: We thank our colleagues Dr. Alexander Michel
(Schering AG, Germany) and Dr. Ginette B. Jacob (Berlex
Laboratories Inc, USA) for their comments on our paper
“Transplacental passage of a nonionic contrast agent” [5].
The propositus who was the subject of the article under
discussion was born 10 days following intravenous ad-
ministration of iopromide (Ultravist) to his mother, and the
nonionic contrast monomer was still detectable in the
cerebral spinal fluid 9 days after birth. Therefore, we made
a brief statement in the discussion regarding the potential
neurotoxicity of the contrast agent used, as we could find
repeated scientific information supplied by Schering AG or
Berlex Inc. (an US affiliate of Schering AG, Germany) on
the contraindication of iopromide for intrathecal use.
Moreover, a paper by Wible et al. [6] reported severe
neurotoxicity of non-ionic X-ray contrast media (iopro-
mide and others) following intracisternal administration in
a rat model that led to death, convulsions, apnea, hypoac-
tivity and coma. Unfortunately this last reference was
accidentally replaced by us during a revision procedure
with the – in this context – non-relevant article by Caillé et
al [1]. For this, we offer an apology to our correspondents
and to the editor for this unintended reference mismatch.
However, with respect to the scientific safety information
on the drug Ultravist we were confronted with contradictory
data during our literature search. In the instruction leaflet
supplied to date with the medication package by
Schering AG in Belgium the indications for Ultravist 240,
300 and 370 are “contrast enhancement in computerized
tomography (CT), digital subtraction angiography (DSA),
intravenous urography, flebography, visualization of body
cavities (e.g. arthrography, hysterosalpingography, fistulo-
graphy) with the exception of myelography, ventriculogra-
phy, cisternography” (sic) [3]. In the scientific leaflet
“Ultravist Safety Information” updated in 2004 by
Berlex Inc (USA) we also read: “Ultravist injection is not
indicated for intrathecal use. Serious adverse reactions have
been reported due to the inadvertent intrathecal administra-
tion of iodinated contrast media that are not indicated for
intrathecal use. These serious adverse reactions include:
death, convulsions, cerebral hemorrhage, coma, paralysis,
arachnoiditis, acute renal failure, cardiac arrest, seizures,
rhabdomyolysis, hyperthermia, and brain edema" (sic) [2].
Conversely, in the detailed drug prescribing information
(updated in 2002) supplied by Schering AG, Germany, we
still find a contradictory statement in relation to the diag-
nostic indications for Ultravist 240: “Contrast enhancement
in computerized tomography (cranial CT), arteriography
and venography including intraarterial digital subtraction
angiography (DSA); intravenous urography, examination of
the subarachnoid space and other body cavities (e.g.
arthrography, hysterosalpingography)” (sic) [4].
On the basis of these statements, our correspondents
should agree on the fact that depending on where the drug
iopromide is supplied worldwide serious adverse reactions
with intrathecal use are obviously interpreted inconsis-
tently. It is generally assumed that regulatory approvals
may differ from one country to another leading, for in-
stance, to the approval of intrathecal use of iopromide in
certain countries and not in others. Conversely, we propose
that scientific safety information provided to the physician
by pharmaceutical companies should be unequivocal and
rigorously identical independent of the country in which
the medication is prescribed. We fully agree with the
manufacturer that it has not yet been sufficiently demon-
strated that Ultravist is safe for use in pregnant patients.
Yours sincerely,
Piet Vanhaesebrouck, M.D., PhD.
Neonatal Intensive Care Unit, 9000 Ghent, Belgium
piet.vanhaesebrouck@UGent.be
P. Vanhaesebrouck (*)
Neonatal Intensive Care Unit,
9000 Ghent, Belgium
e-mail: piet.vanhaesebrouck@UGent.be
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